Form 4: Purple Innovation Issues Warrants to Coliseum Capital as Part of Credit Agreement Amendment

Purple Innovation issued warrants to Coliseum Capital and related entities as partial consideration for a $19 million loan to a subsidiary, according to a Form 4 filing.

Summary

• Purple Innovation issued warrants to Coliseum Capital Partners, L.P. (CCP) and a separate account investment advisory client of Coliseum Capital Management, LLC (CCM) as partial consideration for a $19 million loan made to a subsidiary.
• The warrants were issued pursuant to the First Amendment to the Amended and Restated Credit Agreement, dated March 12, 2025.
• CCP directly owns 16,124,697 warrants, and the separate account directly owns 3,547,434 warrants.
• Each warrant entitles the holder to purchase one share of Purple Innovation's Class A common stock at a price of $1.50 per share, subject to adjustment.
• The warrants are subject to a contractual limitation preventing exercise if it would result in the holder (and affiliates) owning over 49.9% of the outstanding Class A common stock.
• As of March 7, 2025, there were 107,545,493 shares of Class A Common Stock outstanding, allowing for the exercise of warrants for an aggregate of 13,600,617 shares.
• The filing also identifies Coliseum Capital Management, LLC, Coliseum Capital, LLC, Coliseum Capital Partners, L.P., Coliseum Capital Co-Invest III, L.P., Adam Gray, and Christopher Shackelton as reporting persons with potential beneficial ownership.
• Adam Gray is a director of Purple Innovation, and therefore, CCM, CC, CCP, CCC III and Shackelton may be deemed directors by deputization.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the loan provides capital, the issuance of warrants introduces potential dilution. The involvement of Coliseum Capital is a positive signal, but the overall impact is dependent on Purple Innovation's future performance.

Positives

• The $19 million loan provides Purple Innovation's subsidiary with additional capital.
• The issuance of warrants as partial consideration may conserve cash for Purple Innovation.

Negatives

• The issuance of warrants could dilute existing shareholders if exercised.
• The $1.50 exercise price could be seen as low if the stock price appreciates significantly.

Risks

• The warrant exercise limitation at 49.9% could impact Coliseum Capital's ability to fully realize the potential value of the warrants.
• The value of the warrants is dependent on the future performance of Purple Innovation's stock price.
• The loan to the subsidiary could indicate financial challenges within the company.

Future Outlook

The document does not contain explicit forward-looking statements regarding Purple Innovation's future performance, but the issuance of warrants suggests an expectation of future stock price appreciation to incentivize exercise.

Industry Context

Issuing warrants as part of a financing agreement is a relatively common practice, particularly for companies seeking capital while managing cash flow. The involvement of Coliseum Capital, a known investor, could signal confidence in Purple Innovation's potential.

Comparison to Industry Standards

• Warrant issuances are often seen in similar situations where companies are seeking financing, especially in sectors like retail and consumer goods where Purple Innovation operates.
• The exercise price of $1.50 would need to be compared to the current and historical trading prices of PRPL to assess its attractiveness relative to industry norms.
• Similar transactions involving warrant issuances can be found in companies like Casper Sleep (before its acquisition) and other publicly traded mattress and bedding companies.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised.
• The loan provides financial support to a subsidiary, potentially benefiting employees and suppliers.
• Creditors may view the loan as a sign of increased risk, depending on the company's overall financial health.

Key Dates